We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study.
- Authors
Rogé, Maximilien; Salleron, Julia; Kirova, Youlia; Guigo, Marin; Cailleteau, Axel; Levy, Christelle; Leheurteur, Marianne; Nebbache, Rafik; Rivin Del Campo, Eleonor; Lazarescu, Ioana; Servagi, Stéphanie; Aumont, Maud; Thariat, Juliette; Thureau, Sébastien
- Abstract
Simple Summary: Inflammatory breast cancer is a rare entity associated with a poor prognosis, especially for the triple-negative subtype. This study investigates the independent prognostic value of tumour and nodal responses after neoadjuvant chemotherapy. It shows that tumour and lymph node responses did not have the same prognostic value regarding HR and HER2 statuses. We identified a subgroup of patients with triple-negative inflammatory breast cancer with residual lymph node disease for whom adjuvant treatment intensification may be worth investigating. Inflammatory breast cancer (IBC) is a rare entity with a poor prognosis. We analysed the survival outcomes of patients with nonmetastatic IBC and the prognostic value of tumour or nodal responses to assess their individual prognostic impact across IBC subtypes. This retrospective multicentre study included patients diagnosed with IBC between 2010 and 2017 to account for advances in neoadjuvant systemic therapies and modern radiotherapy at seven oncology centres in France. Three hundred and seventeen patients were included and analysed. After a median follow-up of 52 months, the 5-year DFS was lower for triple-negative (TN) (50.1% vs. 63.6%; p < 0.0001). After multivariate analyses, incomplete nodal response was the only significant prognostic factor in the triple-negative group (HR:6.06). The poor prognosis of TN-IBC was reversed in the case of nodal response after neoadjuvant chemotherapy. Breast response does not appear to be a decisive prognostic factor in patients with TN-IBC compared to lymph node response. Despite improvements in neoadjuvant treatments, IBC remains associated with a poor prognosis. In TN-IBC patients, lack of pathological complete node response was associated with poorer survival than any other group. Treatment intensification strategies are worth investigating.
- Subjects
FRANCE; BREAST cancer prognosis; ADJUVANT chemotherapy; SPECIALTY hospitals; INFLAMMATION; TREATMENT effectiveness; CANCER patients; CANCER treatment; COMBINED modality therapy; BREAST tumors
- Publication
Cancers, 2022, Vol 14, Issue 16, p3928
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers14163928